07:00 , Jun 25, 2007 |  BC Week In Review  |  Company News

Benitec scientific advisory board update

Benitec Ltd. (ASX:BLT), Hawthorne East, Australia   Business: Functional genomics, Proteomics   Appointed: John Rossi, professor of molecular biology at the Beckman Research Institute of the City of Hope; Cy Stein, professor of medicine, urology...
07:00 , Jul 24, 2006 |  BioCentury  |  Strategy

From A to Z to CSL

Two decades after it was founded and one decade after it went public, Zenyth Therapeutics Ltd. is being acquired by fellow Australian company CSL Ltd. for A$102.7 million ($77.3 million) in cash. Zenyth, formerly Amrad...
08:00 , Jan 30, 2006 |  BioCentury  |  Strategy

Serono chronicles

Serono chronicles Selected events tracked against Serono's weekly stock price since the company listed on the NYSE in 2000. 1/27/00 - Exclusively licenses recombinant leukemia inhibitory factor (LIF) from Amrad (now Zenyth Therapeutics) for development...
07:00 , Oct 3, 2005 |  BC Week In Review  |  Company News

Amrad antibodies, inflammation, cancer news

AML will change its name to Zenyth Therapeutics Ltd. and its ticker symbol to ZTL. Amrad Corp. Ltd. (ASX:AML), Richmond, Australia   Business: Antibodies, Inflammation, Cancer  ...
07:00 , Aug 23, 2004 |  BioCentury  |  Strategy

Aerovance finds breathing room

Aerovance Inc. is slated to announce today that it has spun out of Bayer Pharmaceuticals Corp., backed by a $32 million series B round led by Apax Partners. The new company focuses exclusively on developing...
07:00 , Jun 28, 2004 |  BC Week In Review  |  Company News

Amrad, Avexa deal

AML said it will spin out its anti-infectives business to create Avexa. AML shareholders will own about 80% of the new entity, and AML will hold about 20%. Avexa will receive AUS$12 million (US$8.3 million)...
07:00 , Jun 21, 2004 |  BC Extra  |  Company News

Amrad to spin out Avexa

Allergy, inflammation and infectious diseases company Amrad (ASX:AML) said it will spin out its anti-infectives business into Avexa (Richmond, Australia). AML shareholders will be entitled to about 80% of the new entity, and AML will...
08:00 , Mar 15, 2004 |  BioCentury  |  Strategy

Fitting in with Merck

Fitting in with Merck Compound Status Target/MOA Alzheimer's disease c-9136 Ph II NA c-7617 Ph I NA c-9138 Ph I NA Acumen deal Preclin/ disc Vaccines, antibodies targeting amyloid-derived diffusible ligand (ADDL) Sunesis deal Preclin/...
08:00 , Nov 24, 2003 |  BC Week In Review  |  Company News

Amrad, Merck deal

AML received a $3 million milestone from MRK subsidiary Merck Sharp & Dohme Pty. Ltd. (Sydney, Australia) as part of their June deal to develop compounds based on AML's cytokine IL-13 receptor alpha targets for...
07:00 , Jun 30, 2003 |  BC Week In Review  |  Company News

Amrad, Merck deal

AML and MRK’s Merck Sharp & Dohme Pty. Ltd. subsidiary (Sydney, Australia) partnered to develop drugs for respiratory disease, including asthma, and cancer. Merck will receive an exclusive license to AML’s cytokine IL-13 receptor alpha...